RESUMO
Incomplete block crossover trials with period-specific baseline and post-baseline (outcome) measures for each subject are often used in clinical drug development; without loss of generality, we focus on the three-treatment two-period ( 3×2 ) crossover. Data from such trials are commonly analyzed using a mixed effects model with indicator terms for treatment and period, and an unstructured covariance matrix for the vector of intra-subject measurements. It is well-known that treatment effect estimates from this analysis are complex functions of both within-subject and between-subject treatment contrasts. We caution that the associated type I error rate and power for hypothesis testing can be non-trivially influenced by how the baselines are utilized. Specifically, the mixed effects analysis which uses change from baseline as the dependent variable is shown to consistently underperform corresponding analyses in which the outcome is the dependent variable and linear combinations of the baselines are used as period-specific and/or period-invariant covariates. A simpler fixed effects analysis of covariance involving only within-subject contrasts is also described for small sample situations in which the mixed effects analyses can suffer from increased type I error rates. Theoretical insights, simulation results and an illustrative example with real data are used to develop the main points.
Assuntos
Estudos Cross-Over , Análise de Dados , Projetos de Pesquisa , Algoritmos , Análise de Variância , Pesquisa Biomédica , Interpretação Estatística de Dados , Modelos EstatísticosRESUMO
BACKGROUND: Variability in measures of mineral metabolism has not been studied in pediatric end stage kidney disease. We sought to determine the intra-individual variability in measures of mineral metabolism in children on hemodialysis (HD) and its impact on clinical decision-making. METHODS: We conducted a prospective single-center study of children (3.6-17.3 years old) on chronic HD. Serial twice weekly measures of serum calcium, phosphate and intact parathyroid hormone (PTH), as well as weekly measures of fibroblast growth factor 23 (FGF23) and vitamin D metabolites, were obtained over a 12-week period in 10 children. Samples (n = 226) were assayed in a single batch at the end of the study. RESULTS: The median intra-individual coefficient of variation (CV) calculated by 4-week blocks was 5.1-6.5% for calcium, 9.5-14.9% for phosphate and 32.7-33.4% for PTH. The median overall CV for FGF23 was 44.4%. Using the first value of each block as a reference, subsequent values would dictate a discrepant management decision 33-56%, 19-28%, and 30-33% of the time for calcium, phosphate, and PTH, respectively. Adjusting for sex and age, most of the variability in phosphate and PTH was attributable to within-participant variability. For calcium, 49% of the variability was attributable to day of blood collection (Monday vs. Friday). The median (range) of an individual participant's values within clinical target ranges was 55% (26-86%) for calcium, 58% (0-96%) for phosphate, and 21% (0-64%) for PTH. CONCLUSIONS: There is considerable intra-individual variability in measures of mineral metabolism that serve as surrogate markers for bone health in children on HD. Within a 4-week period, at least 20-30% of measures would dictate a discrepant decision from the referent measure of that month. These findings have important implications for clinical decision-making and underscore the need to base therapeutic decisions on trends rather than single measurements.
Assuntos
Variação Biológica da População , Tomada de Decisão Clínica/métodos , Falência Renal Crônica/sangue , Minerais/metabolismo , Diálise Renal/efeitos adversos , Adolescente , Biomarcadores/sangue , Osso e Ossos/metabolismo , Cálcio/sangue , Criança , Pré-Escolar , Feminino , Fator de Crescimento de Fibroblastos 23 , Fatores de Crescimento de Fibroblastos/sangue , Humanos , Falência Renal Crônica/terapia , Estudos Longitudinais , Masculino , Minerais/sangue , Hormônio Paratireóideo/sangue , Fosfatos/sangue , Estudos Prospectivos , Diálise Renal/métodos , Vitamina D/sangue , Vitamina D/metabolismoRESUMO
This population-based retrospective cohort study sought to determine if anorexia nervosa (AN) is associated with a higher risk of urolithiasis. Nine thousand three hundred two females with AN were compared to 92 959 randomly selected age-matched and practice-matched females. Cox regression was used to estimate the hazard ratio (HR) for urolithiasis and evaluate effect modification by age. Twenty-three participants with AN (0.25%) developed urolithiasis compared with 154 unexposed participants (0.17%) over a median of 4 years of observation. The risk of urolithiasis varied significantly with age (interaction p = 0.02). AN was associated with a more than threefold higher risk of urolithiasis in females ≤25 years of age (HR 3.49, 95% CI: 1.56-7.81; p = 0.002), but not in females over 25 years (HR 1.18, 95% CI: 0.69-2.02; p = 0.54). The distribution of diagnosis codes for urolithiasis differed between groups (p = 0.04), with a higher proportion of codes for uric acid urolithiasis in the AN (16.2%) versus unexposed group (5.0%). Copyright © 2017 John Wiley & Sons, Ltd and Eating Disorders Association.
Assuntos
Anorexia Nervosa/epidemiologia , Urolitíase/epidemiologia , Adolescente , Adulto , Feminino , Humanos , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Medição de Risco , Adulto JovemRESUMO
In this study we sought to determine if among individuals with urolithiasis, extracorporeal shock wave lithotripsy (SWL) and ureteroscopy are associated with a higher risk of incident arterial hypertension (HTN) and/or chronic kidney disease (CKD). This was measured in a population-based retrospective study of 11,570 participants with incident urolithiasis and 127,464 without urolithiasis in The Health Improvement Network. Patients with pre-existing HTN and CKD were excluded. The study included 1319 and 919 urolithiasis patients with at least one SWL or URS procedure, respectively. Multivariable Cox regression was used to estimate the hazard ratio for incident CKD stage 3-5 and HTN in separate analyses. Over a median of 3.7 and 4.1 years, 1423 and 595 of urolithiasis participants developed HTN and CKD, respectively. Urolithiasis was associated with a significant hazard ratio each for HTN of 1.42 (95% CI: 1.35, 1.51) and for CKD of 1.82 (1.67, 1.98). SWL was associated with a significant increased risk of HTN 1.34 (1.15, 1.57), while ureteroscopy was not. When further stratified as SWL to the kidney or ureter, only SWL to the kidney was significantly and independently associated with HTN 1.40 (1.19, 1.66). Neither SWL nor ureteroscopy was associated with incident CKD. Since urolithiasis itself was associated with a hazard ratio of 1.42 for HTN, an individual who undergoes SWL to the kidney can be expected to have a significantly increased hazard ratio for HTN of 1.96 (1.67, 2.29) compared with an individual without urolithiasis.